What is Soligenix Financial Strength?
Soligenix has the Financial Strength Rank of 6.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
GuruFocus does not calculate Soligenix's interest coverage with the available data.
As of today, Soligenix's Altman Z-Score is 0.00.
Competitive Comparison of Soligenix's Financial Strength
For the Biotechnology subindustry, Soligenix's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Soligenix's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Soligenix's Financial Strength distribution charts can be found below:
* The bar in red indicates where Soligenix's Financial Strength falls into.
Soligenix Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Soligenix's Interest Expense for the
months ended in Dec. 2023 was $0.00 Mil. Its Operating Income for the
months ended in Dec. 2023 was $-2.13 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.12 Mil.
Soligenix's Interest Coverage for the quarter that ended in Dec. 2023 is
| GuruFocus does not calculate Soligenix's interest coverage with the available data. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Soligenix's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Soligenix has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Soligenix (Soligenix) Business Description
Traded in Other Exchanges
N/A
Address
29 Emmons Drive, Suite B-10, Princeton, NJ, USA, 08540
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
Executives
| Timothy R. Cote |
director |
3529 TILDEN STREET, NW, WASHINGTON DC 20008 |
| Richard Straube |
officer: CMO |
29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540 |
| Christopher Schaber |
director, officer: Chairman, CEO and President |
29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540 |
| Jonathan L. Guarino |
officer: Chief Financial Officer |
100 WELLESLEY WAY, FREEHOLD NJ 07728 |
| Oreola Donini |
officer: CSO |
29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540 |
| Robert J. Rubin |
director |
7901 SPRINGER ROAD, BETHESDA MD 20817 |
| Anthony Gregg Lapointe |
director |
PO BOX 83216, GAITHERSBURG MD 20883-3216 |
| Diane L. Parks |
director |
29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540 |
| Jerome B Zeldis |
director |
8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258 |
| Mark E. Pearson |
director, 10 percent owner |
3031 TISCH WAY, SUITE 505, SAN JOSE CA 95128 |
| Preta Martina Cavazza |
other: Former 10% Owner |
VIA SUDAFRICA 20, ROME L6 00144 |
| Enrico Cavazza |
other: Former 10% Owner |
VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040 |
| Silvia Cavazza |
other: Former 10% Owner |
VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040 |
| Francesca Cavazza |
other: Former 10% Owner |
VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040 |
| Spa Essetifin |
10 percent owner |
VIA SUDAFRICA 20, ROME L6 00144 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SNGX has been successfully added to your